Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. (Registro nro. 9173)
[ vista simple ]
000 -CABECERA | |
---|---|
Campo de control de longitud fija | 03005na a2200337 4500 |
003 - IDENTIFICADOR DEL NÚMERO DE CONTROL | |
Campo de control | PC9173 |
005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN | |
Campo de control | 20181105122917.0 |
008 - CÓDIGOS DE INFORMACIÓN DE LONGITUD FIJA | |
Campo de control de longitud fija | 130622s2013 xxx||||| |||| 00| 0 eng d |
040 ## - FUENTE DE LA CATALOGACIÓN | |
Centro transcriptor | H12O |
041 ## - CÓDIGO DE LENGUA | |
Código de lengua del texto/banda sonora o título independiente | eng |
100 ## - PUNTO DE ACCESO PRINCIPAL - NOMBRE DE PERSONA | |
Nombre de persona | Ortiz Romero, Pablo Luis |
9 (RLIN) | 1223 |
Término indicativo de función | Dermatología Médico-Quirúrgica y Venereología |
245 00 - MENCIÓN DE TÍTULO | |
Título | Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. |
Tipo de material | [artículo] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
Nombre del editor distribuidor etc. | European Journal of Cancer, |
Fecha de publicación distribución etc. | 2013 |
300 ## - DESCRIPCIÓN FÍSICA | |
Extensión | 49(2):386-94. |
500 ## - NOTA GENERAL | |
Nota general | Formato Vancouver: Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013 Jan;49(2):386-94. |
501 ## - NOTA DE “CON” | |
Nota de "Con" | PMID: 22981498 |
504 ## - NOTA DE BIBLIOGRAFÍA; ETC. | |
Nota de bibliografía etc. | Contiene 33 referencias |
520 ## - NOTA DE SUMARIO; ETC. | |
Sumario etc. | Background: Panobinostat is a potent, oral pan-deacetylase inhibitor (pan-DACi) that increases the acetylation of proteins involved in multiple oncogenic pathways. Here, panobinostat is studied in bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma (CTCL). Patients and methods: Patients with CTCL subtypes mycosis fungoides and Sezary syndrome who received >= 2 prior systemic therapy regimens received panobinostat (20 mg) three times every week. The primary objective was overall response rate (ORR) as determined by a combined evaluation of skin disease and involvement of lymph node and viscera. Disease progression was defined as an unconfirmed, >= 25% increase in modified Severity Weighted Assessment Tool (mSWAT) compared with nadir. Results: Seventy-nine bexarotene-exposed and 60 bexarotene-naive patients were enrolled. Reductions in baseline mSWAT scores were observed in 103 patients (74.1%). The ORR was 17.3% in all patients in the primary analysis (15.2% and 20.0% in the bexarotene-exposed and -naive groups, respectively). The median progression-free survival was 4.2 and 3.7 months in the bexarotene-exposed and -naive groups, respectively. The median duration of response was 5.6 months in the bexarotene-exposed patients and was not reached at data cutoff in the bexarotene-naive patients. Additional responses were observed when less-stringent progression criteria were used. The most common adverse events were thrombocytopenia, diarrhoea, fatigue and nausea. Thrombocytopenia and neutropenia were the only grade 3/4 adverse events in > 5% of patients and were manageable. Conclusion: Despite a very conservative definition of disease progression, panobinostat demonstrated activity with a manageable safety profile in bexarotene-exposed and -naive CTCL patients. |
710 ## - PUNTO DE ACCESO ADICIONAL - NOMBRE DE ENTIDAD | |
9 (RLIN) | 145 |
Nombre de entidad o nombre de jurisdicción como elemento inicial | Servicio de Dermatología Médico-Quirúrgica y Venereología |
856 ## - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS | |
Identificador Uniforme del Recurso (URI) | http://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/9/pc9173.pdf |
Acceso | Solicitar documento |
942 ## - ENTRADA PARA ELEMENTOS AGREGADOS (KOHA) | |
Suprimido en OPAC | Público |
Fuente de clasificación o esquema de ordenación en estanterías | |
Koha [por defecto] tipo de item | Artículo |
Suprimido | Estado de pérdida | Fuente de clasificación o esquema de ordenación en estanterías | Estropeado | No para préstamo | Localización permanente | Localización actual | Fecha de adquisición | Signatura completa | Fecha última consulta | Fecha del precio de reemplazo | Tipo de item de Koha |
---|---|---|---|---|---|---|---|---|---|---|---|
Hospital Universitario 12 de Octubre | Hospital Universitario 12 de Octubre | 2018-11-05 | PC9173 | 2018-11-05 | 2018-11-05 | Artículo |